December 8, 2021 Non Regulatory InDex Pharmaceuticals enrols first patient in the PK study with cobitolimod Read more
November 10, 2021 Non Regulatory InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2022 Annual General Meeting Read more
November 8, 2021 Non Regulatory InDex Pharmaceuticals presents at Redeye Life Science Day 2021 Read more
August 23, 2021 Non Regulatory InDex Pharmaceuticals strengthens the clinical development organization in preparation of the start of the phase III study CONCLUDE with cobitolimod Read more
April 7, 2021 Non Regulatory InDex Pharmaceuticals gets patent for additional DIMS compounds granted in Europe Read more
March 30, 2021 Non Regulatory InDex Pharmaceuticals enters agreement with Parexel Biotech for phase III clinical study of cobitolimod for ulcerative colitis Read more
March 15, 2021 Non Regulatory InDex Pharmaceuticals Holding AB (publ) announces changes in the Nomination Committee for the 2021 Annual General Meeting Read more
March 10, 2021 Non Regulatory InDex Pharmaceuticals presents at Barclays Global Healthcare Conference and Carnegie Nordic Virtual Healthcare Seminar Read more